Certainly a sense of deja vu in all this. Wash, spin, rinse, do it all again. However, its been a long path with Yale, and the learning gained could deliver a better outcome. This deal is just for Ovarian cancer, so its a win to have a number of parallel paths working. Perhaps there is another one in the wings?
Add to My Watchlist
What is My Watchlist?